Cugene presents promising preclinical data on VitoKine-2, a precision-engineered tumor-activable IL-2 therapeutic designed to target tumor-infiltrating lymphocytes (TIL) in the tumor microenvironment (TME). Utilizing a unique masking technology, VitoKine-2 remains inert until activated, minimizing peripheral T cell activation and reducing systemic toxicities. VitoKine is a potential first-in-class biotherapeutic that can be administered monthly at a high-dose, enlarging the therapeutic window for both IO-responsive and unresponsive patients. 

CUG252 advances to Phase1b studies for patients with mild-to-moderate Systemic Lupus Erythematosus (SLE). The trial is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of this novel treatment, and aiming to assess its efficacy and determine its potential for broader clinical application.

AbbVie and Cugene Inc., a clinical-stage biotechnology company focused on developing next-generation precision immunology and oncology medicines to treat autoimmune disease and cancer, today announced an exclusive worldwide license option agreement for CUG252, a potential best-in-class Treg-selective IL-2 mutein, as well as other novel IL-2 muteins, for the potential treatment of autoimmune and inflammatory diseases. Read More

Cugene unveils preclinical data on TILKine-2, showcasing its robust anti-tumor efficacy through TIL-targeting, cis-activation and expansion at the tumor site. This approach reduces systemic toxicity and enhances the therapeutic window, positioning TILKine-2 as a strong therapeutic agent for further clinical development.

Cugene is launching its first-in-human study for subcutaneously administered CUG252 in healthy volunteers, evaluating its safety, tolerability, pharmacokinetics and pharmacodynamics.

Cugene recently delivered an oral presentation on CUG252, a long-acting Treg-selective IL-2 with high specificity and low toxicity, aimed at restoring immune homeostasis and self-tolerance for treating autoimmune and inflammatory diseases. CUG252 shows a promising best-in-class profile among IL-2 variants, offering superior Treg selectivity while maintaining potency comparable to wild-type IL-2.